Oxymetazoline
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Oxymetazoline: From Pharyngitis and Common Cold to Nasal Cavity Disease
One-Sentence Summary
Oxymetazoline is a topical alpha-adrenergic decongestant, originally used for pharyngitis and the common cold. The TxGNN model predicts it may be effective for nasal cavity disease, but the data compiled for this report show no registered clinical trials and only 5 loosely related publications, none of which is a controlled efficacy study in humans.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Pharyngitis, common cold |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 0.9996 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, oxymetazoline is a topical alpha-adrenergic agonist. It acts on alpha-1 and alpha-2 receptors, and it also binds several serotonin receptors (5-HT1B, 5-HT1D, 5-HT2C). Its main effect is constriction of blood vessels in the nasal lining, which reduces swelling and congestion and improves airflow.
Nasal cavity disease is a broad category, and the drug’s original uses (common cold, pharyngitis) already involve nasal congestion. The prediction is therefore mechanistically coherent. However, the very high score probably reflects how close the new indication is to the existing one, rather than a genuinely new repurposing signal.
Two other predicted indications were also reviewed:
- Headache disorder (score 0.9904): a small body of literature explores intranasal tetracaine plus oxymetazoline for status migrainosus. The effect cannot be attributed to oxymetazoline alone because it was given in combination (evidence level L4).
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9929658 | 1998 | Clinical study | Ann N Y Acad Sci | Olfactory function and nasal volume measured in 36 subjects during acute rhinitis (common cold) |
| 8615587 | 1996 | Animal study | Ann Otol Rhinol Laryngol | Oxymetazoline nose drops tested in a rabbit model of acute bacterial sinusitis, assessing effects on local tissue defence |
| 25496205 | 2015 | Cohort | J Plast Surg Hand Surg | Nasal patency measured by acoustic rhinometry in children after cleft lip and palate repair (indirectly related) |
| 28490409 | 2017 | Case series | Am J Rhinol Allergy | Endoscopic coblation for nasal telangiectasias in hereditary hemorrhagic telangiectasia (indirectly related) |
| 38024464 | 2023 | Case report | Glob Pediatr Health | Rhinoscleroma in a 9-year-old boy, a rare granulomatous nasal disease (indirectly related) |
Evidence for the headache-disorder prediction is listed here separately:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31919839 | 2020 | Clinical study (combination therapy) | Headache | Intranasal 3% tetracaine plus 0.05% oxymetazoline in status migrainosus; design not confirmed |
| 23575821 | 2013 | Case report | Cephalalgia | Unilateral nasal pain with migraine features |
| 36425231 | 2022 | Review | Health Psychol Res | Drug interactions with MAO inhibitors; relevant to safety (possible hypertensive reactions with sympathomimetics) |
India Market Information
Twenty valid single-ingredient registrations are listed. The approved indication text is not available for any of them. Five main registrations:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 39513 | Clinovin 0.5mg Nasal Drops | Nasal drops (10 ml bottle) | Not available |
| 42548 | Cinus 0.5mg Nasal Drops | Nasal drops (10 ml) | Not available |
| 155813 | Nosivak 0.05% Nasal Spray | Nasal spray (10 ml bottle) | Not available |
| 164353 | Optolin Eye Drop | Eye drop (5 ml bottle) | Not available |
| 134810 | Maxtra-O Nasal Spray | Nasal solution (10 ml bottle) | Not available |
Strengths range from 0.01% (infant) and 0.025% (paediatric) to 0.05% (adult). Most products are nasal drops or sprays, and one is an eye drop.
Safety Considerations
- Contraindications suggested by the knowledge graph (these come from model-level disease associations, not label text): hypertension, heart disease, coronary artery disease, atherosclerosis, diabetes mellitus and diabetic ketoacidosis, benign prostatic hyperplasia, angle-closure glaucoma, hyperthyroidism (Graves disease, thyrotoxicosis), eye infections and conjunctivitis, and vision disorders.
- Drug interactions: Pharmacology records show binding to alpha-1 (A, B, D) and alpha-2 (A, B, C) adrenoceptors and to 5-HT1B, 5-HT1D and 5-HT2C receptors. Published literature also flags a risk of hypertensive reactions when sympathomimetics are combined with MAO inhibitors.
Package insert warnings and contraindications were not available, so please refer to the package insert for the full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction, nasal cavity disease, largely overlaps with oxymetazoline’s existing use for nasal congestion, so it adds little new repurposing value. No clinical trials exist, and the literature is indirect, animal-based or low-level. The headache-disorder prediction is the more novel direction, but it rests on combination-therapy data and could be treated as a research question rather than a decision candidate.
To proceed, the following is needed:
- Package insert warnings and contraindications from Indian regulatory sources (a blocking gap for safety screening)
- Approved indication text for the registered products
- Detailed mechanism of action data
- Controlled clinical evidence for a defined, genuinely new indication (for example, an oxymetazoline-alone study in migraine or headache)
- A clear definition of which nasal cavity conditions go beyond the existing congestion indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.